Table 3.
Viral hepatitis status and anti-viral treatment among patients with hepatitis C (n = 23).
| Anti-HCV and HCV RNA (IU/ml)) | Known cirrhosis | ALT (U/L) | AST (U/L) | Anti-viral treatment | Time between starting antiviral and ICI (months) |
|---|---|---|---|---|---|
| Anti-HCV+/RNA undetectable | Y | 64 | 87 | IFN + Ribavirin | 234 |
| Anti-HCV+/no RNA not available | Y | 42 | 70 | N | NA |
| Anti-HCV+/no RNA not available | Y | 30 | 56 | Ledipasvir-Sofosbuvir | NA |
| Anti-HCV+/RNA undetectable | Y | 32 | 16 | Ledipasvir-Sofosbuvir | 18 |
| Anti-HCV/RNA: 1800 000 | Y | 30 | 84 | N | |
| Anti-HCV+/no RNA not available | Y | 28 | 63 | Ledipasvir-Sofosbuvir | 28 |
| Anti-HCV+/RNA: 812 000 | Y | 51 | 119 | Ledipasvir-Sofosbuvir | 18 |
| Anti-HCV+/RNA undetectable | Y | 50 | 61 | Ledipasvir-Sofosbuvir | 37 |
| Anti-HCV+/RNA: 149 000 | N | 103 | 97 | N | NA |
| Anti-HCV+/RNA 954 000 | Y | 139 | 250 | IFN + Ledipasvir-Sofosbuvir | 44 |
| Anti-HCV+/RNA undetectable | Y | 62 | 80 | Ledipasvir-Sofosbuvir | 13 |
| Anti-HCV+/RNA 25 700 | Y | 69 | 101 | Ledipasvir-Sofosbuvir | 9 |
| Anti-HCV+/RNA undetectable | Y | 72 | 232 | IFN + Ribavirin + Boceprevir | NA |
| Anti-HCV+/RNA undetectable | Y | 41 | 39 | Elbasvir-Grazoprevir | NA |
| Y | 48 | 46 | N | NA | |
| Anti-HCV+/RNA not available | N | 30 | 33 | IFN | NA |
| Anti-HCV+/RNA undetectable | Y | 44 | 70 | Sofosbuvir-Velpatasvir | 24 |
| Anti-HCV+/RNA undetectable | Y | 38 | 100 | Ledipasvir-Sofosbuvir | 55 |
| Anti-HCV+/RNA undetectable | N | 20 | 15 | N | NA |
| Anti-HCV+/RNA: 190 000 | Y | 27 | 63 | N | NA |
| Anti-HCV+/RNA undetectable | Y | 37 | 42 | IFN + Ledipasvir-Sofosbuvir | NA |
| Anti-HCV+/no RNA not available | Y | 27 | 97 | NA | 7 |
| Anti-HCV+/RNA undetectable | N | 140 | 107 | IFN | NA |
Abbreviation: NA, non-available.